IL-13 plays an important role in the development of allergic reactions, but it also reduces the production of receptor activator of the nuclear factor kappa-B ligand (RANKL), thereby reducing bone resorption, inactivating the matrix metalloprotease (MMP) 2 and MMP9, thus preventing cartilage destruction, and inhibiting angiogenesis. This evidence concerns the gene TNFSF11 and allergic disease.